North Bay's first funded cardiac rehab program launches in Canadore College
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
3 minutes ago
- CTV News
Study finds more women opted for long-acting IUDs after B.C. made birth control free
A one-month dosage of hormonal birth control pills is displayed in Sacramento, Calif., Aug. 26, 2016. (AP Photo/Rich Pedroncelli, File) A new study finds significantly more women opted for long-acting birth control methods after British Columbia made prescription contraception free. Researchers found prescriptions for all types of birth control jumped significantly after the province began covering the cost of contraception in April 2023, especially for intrauterine devices (IUDs). The study published Monday in the BMJ examined the prescriptions of nearly 860,000 women in the 15 months after contraception coverage began and compared them to what would have been expected without coverage. It found a 49 per cent increase in prescriptions for IUDs, which are inserted into the uterus to prevent fertilization and considered 10 times more effective than pills or condoms. Reached in Vancouver, lead author Laura Schummers said IUDs can cost up to $450 out-of-pocket. 'This tells us that costs alone are a huge barrier to the most effective methods of contraception across Canada,' said Schummers, an assistant professor in the faculty of pharmaceutical sciences at the University of British Columbia. The study says roughly 11,000 additional women chose the more reliable option. It examined prescriptions for women aged 15 to 49 between April 2023 and June 2024. This report by Hannah Alberga, The Canadian Press, was first published July 28, 2025.
CTV News
33 minutes ago
- CTV News
York police charge doctor with two counts of sexual assault
Police in York Region have arrested a doctor on sexual assault charges. York's Criminal Investigations Bureau have charged a doctor with sexual assault after a victim reported two incidences. Police say the person attended a medical clinic on Markham Road. During the visit, the person said the doctor touched them in a sexual manner. The victim left immediately and reported the incident to the police. While telling police of the experience, the person also recalled a previous appointment at the same clinic in November 2023, when the doctor's actions were also inappropriate. At that time, the person didn't report the event because they believed the conduct might have been part of a legitimate medical procedure. Police are asking the public to review the photo of Dr. Saber Abdel Malouka Abdel Malak, 62, of Whitchurch-Stouffville who has been a physician for more than 30 years. Police say a sexual assault includes any non-consensual contact of a sexual nature. They encourage anyone who feels they may have been a victim to report the incident to the police. To make an online report click here. Anyone with information is asked to call the York Regional Police Special Victims Unit at 1-866-876-5423, ext. 7071. Anonymous tips can be made by calling Crime Stoppers at 1-800-222-TIPS.
National Post
an hour ago
- National Post
Hyperfine Swoop® AI-Powered Portable MRI System Demonstrates 100% Sensitivity for ARIA-E Detection in New Data Presented at the 2025 Alzheimer's Association International Conference
Article content Interim results from the CARE PMR study support the use of ultra-low-field MRI as a triage tool for monitoring patients on amyloid-targeting therapies. Article content TORONTO — Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop ® system—announced promising early results from the CARE PMR (Capturing ARIA Risk Equitably with Portable MR) study presented at the 2025 Alzheimer's Association International Conference in Toronto, Canada. Article content Researchers from the Benzinger Lab at Washington University School of Medicine in St. Louis reported interim results from 31 Alzheimer's patients undergoing Lecanemab therapy. Participants were scanned using the Swoop ® system within one week of their clinical high-field MRI scans, as part of the safety monitoring protocol required by the FDA when it approved Lecanemab. Article content The Swoop ® system achieved 100% sensitivity in detecting mild to moderate ARIA-E, a condition marked by cerebral edema. Researchers note that while ultra-low-field MRI is promising as a triage tool to screen for ARIA-E, high-field MRI may remain necessary for comprehensive evaluation in some cases. Article content Appropriate use guidelines for amyloid-targeting therapies, including Lecanemab and Donanemab, require MRI safety monitoring at multiple, specific intervals throughout the course of therapy. However, regular screening with conventional MRI systems is often hindered by high costs, scheduling delays, and logistical challenges for both patients and caregivers. The Swoop ® system addresses these barriers by offering an affordable, portable imaging solution that is readily available to patients at the point of care, such as neurology offices and infusion clinics. Dr. Tammie Benzinger, principal investigator of the study, noted, 'This research could help alleviate the burden on families and facilities and improve overall access to care. We are hoping to expand the project to Washington University's Medical Campus to include community sites offering infusion therapy for early Alzheimer's disease.' Article content These findings from the CARE PMR study underscore the potential of portable MRI to transform ARIA-E monitoring and expand access to care. The Swoop ® system enables clinicians to confidently detect ARIA-E, while offering patients and caregivers the convenience of point-of-care screening, eliminating the need for separate imaging appointments. 'We are proud to collaborate with leading clinicians and researchers who share our vision of advancing Alzheimer's care through accessible innovation,' said Edmond Knopp, MD, Chief Medical Officer at Hyperfine. Article content The CARE PMR study is a collection of data from multiple sites assessing the clinical utility and workflow benefits of using Swoop ® system images to detect amyloid-related imaging abnormalities (ARIA) in Alzheimer's patients receiving amyloid-targeting therapy. It is funded by the Alzheimer's Association and the American Society of Neuroradiology. Article content The Swoop ® Portable MR Imaging ® Systems are U.S. Food and Drug Administration (FDA) cleared for brain imaging of patients of all ages. They are portable, ultra-low-field magnetic resonance imaging devices for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis. Article content About Hyperfine, Inc. Article content Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop ® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop ® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit Article content The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc. The Swoop logo, Optive AI logo, and Optive AI are trademarks of Hyperfine, Inc. Article content Forward-Looking Statements Article content This press release includes 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the 'Company') may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as 'expect,' 'estimate,' 'project,' 'budget,' 'forecast,' 'anticipate,' 'intend,' 'plan,' 'may,' 'will,' 'could,' 'should,' 'believes,' 'predicts,' 'potential,' 'continue,' and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's goals and commercial plans, the benefits of the Company's products and services, and the Company's future performance and its ability to implement its strategy. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company's product development and commercialization activities, including the degree that the Swoop ® system is accepted and used by healthcare professionals; the impact of COVID-19 on the Company's business; the inability to maintain the listing of the Company's Class A common stock on the Nasdaq; the Company's inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company's products and services and reimbursement for medical procedures conducted using the Company's products and services; the Company's estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties indicated from time to time in Company's filings with the Securities and Exchange Commission, including those under 'Risk Factors' therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based. Article content Article content Article content Article content Media Contact Article content Article content Devin Zell Article content Article content Hyperfine Article content Article content dzell@ Article content Investor Contact Article content Article content Webb Campbell Article content Article content
